Introduction: Hericium erinaceus is known as a medicinal edible mushroom owing to its antimicrobial, antioxidant, anti-tumor and immunomodulatory effects. Helicobacter pylori infection is one of the major health concerns worldwide due to its high rate in global populations, frequent recurrence, and rapid emergence of drug-resistant strains. The present study aims to investigate antioxidant, anti-H. pylori, and urease inhibitory activities of solvent fractions from H. erinaceus mycelium and culture filtrate. Methods: H. erinaceus mycelium was purely cultured in a liquid medium. A polysaccharide fraction was obtained from the culture filtrate by precipitation with ethanol. The mycelium and culture filtrate were extracted by liquid extraction to obtain solvent-soluble fractions. The antibacterial effects of these fractions were determined using paper disc diffusion and broth microdilution assays. Urease inhibition was determined using the salicylate-hypochlorite method. The antioxidant activity of H. erinaceus was evaluated via 2,2,1-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity. Results: The ethyl-acetate (EtOAc) fractions derived from H. erinaceus culture filtrate (fEtOAc Fr.) and mycelium (mEtOAc Fr.) showed the strongest anti-H. pylori activity with MIC (MBC) of 1.25 – 1.5 (5.0 – 7.5) mg/mL and potential urease inhibitory activity with IC₅₀ of 0.34 – 0.35 mg/mL. In addition, fEtOAc Fr. exhibited the greatest antioxidant activity (IC₅₀, 11.83 mg/mL), which was slightly stronger than that of mEtOAc Fr. (IC₅₀, 14.75 mg/mL). Moreover, our study also found that the water fractions from the culture filtrate (fWater Fr.) and the mycelium (mWater Fr.) displayed considerable inhibitory activities against bacterial urease (IC₅₀, 1.26 – 1.40 mg/mL), although they showed low or no anti-H. pylori and antioxidant activities. Conclusion: The present study revealed that the EtOAC fractions derived from the H. erinaceus mycelium and culture filtrate potentially have anti-H. pylori, anti-urease and antioxidant activities. These results suggest that H. erinaceus mycelium and culture filtrate could be utilized to develop functional foods and nutraceuticals to prevent H. pylori infection. More research is needed to prove the safety of the H. erinaceus mycelium and culture filtrate fractions and their in vivo efficacy in the treatment of H. pylori infection.

Antibacterial activity Antioxidant Culture filtrate Helicobacter pylori Hericium erinaceus Mycelium

Hericium erinaceus (Bull.) Pers., known as lion’s mane mushroom, grows on old or dead hardwood trees in America and Asia and is widely consumed due to its nutritional qualities and health benefits. The mushroom has long been used as a folk medicine to treat various human diseases in several East Asian countries1. It provides numerous essential nutrients and constituents such as polysaccharides, proteins, lectins, phenols, isoindolinones, hericenones, erinacine terpenoids, and sterols, several of which possess various pharmacological properties2, 3, 4. H. erinaceus extracts showed to be effective in stimulating the synthesis of immune system components2, 5, which contribute to inhibiting tumor cell growth6. The mushroom displayed clinical potential in relieving inflammatory bowel disease by regulating gut microbiota and immune system7. Polysaccharide fraction derived from H. erinaceus has also induced immunomodulating and anti-tumor effects6, anti-gastritis activity, and significantly enhanced skin antioxidant enzymes that help retard skin aging8. In addition, the fruiting body of H. erinaceus has been traditionally used to ameliorate gastrointestinal disorders and treat symptoms related to gastric ulcers7, 9, 10. H. erinaceus extracts were found to have antimicrobial activities against both Gram-positive and -negative pathogenic bacteria11, 12, and both antibiotic-resistant and -susceptible Helicobacter pylori13, a human gastrointestinal pathogen involved in gastritis, duodenal ulcers, and gastric cancer14, 15. Ethanol extracts from H. erinaceus fruiting bodies were reported to exhibit growth inhibitory effects on H. pylori by in vitro and/or in vivo studies9, 10, 13.

Besides, extracts derived from the mycelium culture of H. erinaceus were reported to be active against pathogenic bacteria11, hepatocarcinoma cells16, stimulate nerve growth factor synthesis17, and prevent oxidative stress in human gastric mucosa epithelium cell18. The pure culture of H. erinaceus mycelium has been recently being studied and developed, especially for the production of nutraceuticals and pharmaceuticals. However, there is less information focusing on the antibacterial activity of H. erinaceus mycelium against H. pylori. Therefore, the present study was aimed to assess the possible antioxidant effect and growth-inhibitory, bactericidal, and urease inhibitory activities of the polysaccharide and solvent fractions extracted from mycelium and culture filtrate of H. erinaceus toward H. pylori.

Brucella broth (BB), brain heart infusion broth (BHIB), and bacto-agar were purchased from Becton Dickinson, Inc. (Franklin Lakes, NJ). Newborn bovine serum (NBS) was purchased from Hyclone (Longan, UT). Tryptone and yeast extract were provided by Merck (Kenilworth, NJ) and glucose was provided by HiMedia (Kennett Square, PA). Amoxicillin (≥ 98%) was provided by Santa Cruz Biotechnology Inc. (Dallas, TX). Solvents, hexane 96%, ethyl acetate (EtOAc) 99.8%, absolute ethanol (EtOH), and methanol (MeOH) 99.9% were purchased from Scharlau (Barcelona, Spain). All other chemicals and reagents used in this study were of analytical grade quality and available commercially.

Hericium erinaceus mycelium was provided and identified by Dr. Pham Thanh Ho, Laboratory of Biotransformation, Faculty of Biology and Biotechnology, VNUHCM University of Science, Ho Chi Minh City, Vietnam. H. erinaceus mycelium could produce fruiting bodies in the laboratory conditions. The mycelium and fruiting bodies were cultured and stored at 4 ^oC.

Four pieces of H. erinaceus mycelium (1 cm²/each) from 8 day-old culture on agar medium were inoculated in 500 mL bottles containing 200 mL liquid medium with the following composition: 20% potato extract, 2% glucose, 0.2% yeast extract, and 0.2% tryptone. The broth cultures were incubated at 25 ± 2°C and shaken at 150 rpm for 7 days11. After that, the culture broths were filtered to obtain the mushroom mycelium and culture filtrate for solvent extraction, as shown in Figure 1.

Figure 1

The dry mycelium was disrupted by liquid nitrogen in 30 minutes. The mycelium was then finely grounded and extracted with 200 mL hexane for 1 day (3 times) and further extracted sequentially with 200 mL EtOAc for 1 day (3 times) and 500 mL hot water for 2 hours. The extracts were filtered, and a rotary evaporator was used to remove the solvents to obtain a hexane-soluble fraction (mHexane Fr.), EtOAc-soluble fraction (mEtOAc Fr.), and water-soluble fraction (mWater Fr.) (Figure 1).

The culture filtrate was precipitated with 4 times volume of cold absolute EtOH (1 °C) overnight and then centrifuged to obtain the crude polysaccharide fraction (precipitant). The polysaccharide fraction (PS Fr.) was dissolved in sodium phosphate buffer buffer (30 mM, pH 7) to a 200 mg/mL stock concentration and stored at — 20 °C until further use. After the precipitation, the filtrate was then fractionated sequentially three times with an equal volume of hexane for 2 hours, and then three times with an equal volume of EtOAc for 2 hours using the liquid-liquid method. The solvent-soluble fractions were condensed to dryness by a rotary evaporator at 42 °C to gain the hexane fraction (fHexane Fr.), EtOAc fraction (fEtOAc Fr.), and water fraction (fWater Fr.) (Figure 1).

The H. pylori strain (ATCC 43504) was provided by the Oxford University Clinical Research Unit in Vietnam (OUCRU-VN) and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The bacterial strain was stored in BHIB medium supplemented with 25% glycerol and placed in a nitrogen liquid container until use.

The H. pylori strain was cultured on Brucella agar supplemented with 10% newborn bovine serum, and then incubated at 37°C in 3 days under microaerophilic condition created by a 2.5 L Oxoid anaerojar and Oxoid Campygen sachet (Thermo Fisher Scientific, Waltham, MA, USA). The bacterial suspensions used for bioassay were suspended in Brucella broth supplemented with 5% NBS using a 72-h subculture of H. pylori on Brucella agar. Bacterial density was determined using McFarland turbidity standards.

The antibacterial activity of the fractions extracted from the H. erinaceus mycelium and culture filtrate was evaluated using paper-disc diffusion method, as previously described19. In brief, 100 µL of H. pylori suspensions (10⁸ CFU/mL) were evenly spread on Brucella agar medium in petri plates (Ø 90 mm, SPL Life Sciences, Korea). Sterile paper discs (1 mm thickness, 6 mm diameter) from Whatman/ GE Healthcare (UK) impregnated with 20 µL of respective test material (500 µg/µL) in DMSO were placed on the plate surface. DMSO (20 µL/disc) and amoxicillin (10 µg/disc) were similarly prepared and used as negative and positive controls, respectively. The test and control plates were incubated at 37 °C under the microaerophilic condition for 3 days. After incubation, the inhibition zone was measured. The assay was performed in duplicate three times. The inhibitory responses were classified as follows: very strong response with inhibition zone diameter > 28 mm, strong response with inhibition zone diameter of > 17 – 28 mm, moderate response with inhibition zone diameter of > 13 – 17 mm, weak response with inhibition zone diameter of 8 – 13 mm, and little or no response with inhibition zone diameter < 8 mm.

The minimal inhibitory concentration (MICs) and minimal bactericidal concentration (MBCs) of the fractions extracted from H. erinaceus mycelium and culture filtrate towards H. pylori were evaluated using broth microdilution method, as reported previously19. Briefly, the fractions in DMSO (10 µL each) at various final concentrations (0 – 10 mg/mL) were added to each well of sterile 96-well plates, which contained 40 µL of Brucella broth medium supplemented with 5% NBS. Subsequently, 50 µL bacterial suspension (5.10⁶ CFU/mL) from cultures on Brucella agar was seeded into each well. DMSO and amoxicillin served respectively as negative and positive controls and were similarly prepared. The plates were incubated at 37°C in a gas jar under microaerophilic conditions and shaken at 50 rpm for 48 hours. MIC values were determined as the lowest concentrations that showed bacterial growth inhibition using resazurin as an indicator. MBC values of the test fractions were performed following the MIC assays in 24-well plates with Brucella agar medium as previously described20. MIC and MBC values of each test sample were results from at least three independent experiments performed in triplicate (n ≥ 9).

H. pylori urease crude extract was prepared as reported previously21 with slight modification. Briefly, an amount of 500 mg of H. pylori cell mass from 72-h cultures on NBS-supplemented Brucella agar was spread as thinly as possible on the wall of a polypropylene tube and stored in a nitrogen liquid container for 15 minutes. The cell mass was then thawed at room temperature and added with 5 mL of 20 mM sodium phosphate buffer (pH 7.3) containing EDTA (1 mM). Finally, the mixture was centrifuged at 12,000×g, 4°C for 30 minutes, and the supernatant was filtered using a 0.22 µm Millex GV Millipore filter. The protein content was determined using Bradford protein assay. Bovine serum albumin (BSA) was used as a protein standard.

H. pylori urease inhibitory activity of the fractions extracted from H. erinaceus mycelium and culture filtrate was assayed in 96-well plates using the salicylate-hypochlorite method with minor modification22. In brief, 50 µL of 0.25 µg H. pylori urease crude preparation (0.04 urease units) in EDTA-sodium phosphate buffer (pH 7.3) was added to each well containing 50 µL of the test fraction at various concentrations. The plates were preincubated at 37°C and shaken at 50 rpm for 90 minutes. An amount of 50 µL of 5 mM urea in phosphate buffer saline (PBS) was added into each well. After 30 minutes of incubation, a stop solution consisting of 35 µL of solution A (146% Na salicylate + 0.1% sodium nitroprusside) and 65 µL of solution B (1.78% NaOH + 11.57% Na citrate + 0.54% active NaOCl) were supplemented in sequence to each well. The plates were incubated for 30 minutes at 37°C for color development. The ammonia production released from the hydrolysis of urea by urease activity was quantified by measuring absorbance on the microplate reader at 625 nm using ammonium chloride as a standard. Thiourea as a standard reference was similarly prepared. Inhibition rate (I%) was calculated by the following formula: I (%) = [1 — (OD₆₂₅ test sample — OD₆₂₅ corresponding background)/(OD₆₂₅ control — OD₆₂₅ blank)] × 100. Urease inhibition activity of the fractions was displayed as 50% inhibitory concentration (IC₅₀), which was defined as the concentration of the fractions required to decrease urease activity to 50% of the control value. The assay was performed in duplicate three times.

The antioxidant activities of the fractions extracted from H. erinaceus mycelium and culture filtrate were evaluated via 2,2,1-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity with slight modification11. The experiment was performed in 96-well plates. The fraction solutions in MeOH at various concentrations from 0 – 50 mg/mL were placed in the wells, and 150 µL of 380 µM DPPH in MeOH was then added to each well. Blank and background wells, which contained MeOH and the fractions, respectively, without DPPH, were also prepared. The plates were placed in the dark and incubated at 37°C with rotation at 75 rpm for 30 minutes. Subsequently, the absorbance measurements were determined at 515 nm on a Microlisa Plus microplate reader (Micro Lab Instruments, India). Acid ascorbic (0 – 0.5 mg/mL) served as a positive control and was similarity prepared. The percent radical scavenging activity was calculated as follows: percent scavenging effect (%) = [1 — (OD_treatment — OD_background)/(OD_control — OD_blank)] × 100, where OD_control, OD_blank, OD_treatment, and OD_background are absorbance values of the controls, blanks, fraction treatments, and background wells, respectively.

All bioassays were repeated three to five times in triplicate. The inhibition zones of the test fractions were presented in mean values (± SD). DPPH IC₅₀ and urease IC₅₀ (half maximal inhibitory concentration) values were calculated using GraphPad Prism 5 software program (GraphPad Software, Inc., La Jolla, CA, USA). The IC₅₀ values of the treatments would be declared significantly different if their 95% confidence intervals did not overlap.

After 7 days of incubations, the culture broths of H. erinaceus were filtered to obtain 57.7 g dry weight of the mycelium and 24 L of its culture filtrate. Solvent-soluble fractions obtained from the dry mycelium and culture filtrate are presented in Figure 1.

From the dry mycelium (57.7 g), the three fractions of mHexane Fr., mEtOAc Fr. and mWater Fr. were obtained, and weighed as 0.162, 0.091 and 0.509 g, respectively (Figure 1).

From 24 L of the culture filtrate, the four fractions of PS Fr. (26.4 g), fHexane Fr.(0.12 g), fEtOAc Fr. (11.04 g) and fWater Fr. (72.48 g) were obtained (Figure 1). The yields of the Hexane and EtOAc fractions were lower than those of the PS and Water fractions. This implied that there were very few non-polar components in the mycelium and culture filtrate.

Table 1

Test material (10 mg/disc)	Inhibition zone* (mm)	MIC (mg/mL)	MBC (mg/mL)
fEtOAc Fr.	18.8 ± 0.75 b	1.25	5
mEtOAc Fr.	17.7 ± 1.03 b	1.5	7.5
mHexane Fr.	12.3 ± 0.82 c	7.5	10
PS Fr.	9.3 ± 0.52 d	7.5	> 10
fHexane Fr.	–	10	> 10
mWater Fr.	–	> 10
fWater Fr.	–	> 10
Amoxicillin**	37. 5 ± 2.51a	0.032	0.063

The results from the paper disc diffusion method are summarized in Table 1 and Figure 2. The results revealed that the EtOAc fractions from both the mycelium (mEtOAc Fr.) and filtrate (fEtOAc Fr.) had strong anti-H. pylori activity with inhibition zones of 18 – 19 mm, while mHexane Fr. and PS Fr. showed weak activity with 12 and 9 mm inhibition zones, respectively. However, mWater Fr., fHexane Fr. and fWater Fr. showed no inhibitory activity (Table 1). All fractions displayed weaker inhibitory activity than the positive control amoxicillin (inhibition zone of 37.5 mm).

Figure 2

The MIC and MBC results also yielded similar results (Table 1). The fractions mEtOAC Fr. and fEtOAC Fr. showed strong anti-H. pylori activity with MIC (MBC) values of 1.5 (7.5) and 1.25 (5.0) mg/mL, respectively. However, mHexane Fr. and PS Fr. displayed weak anti-H. pylori activity with MIC (MBC) values of 7.5(≥ 10) mg/mL, while fHexane Fr., mWater Fr. and fWater Fr. showed no inhibitory activity (MIC ≥ 10 mg/mL). The H. pylori ATCC 43504 strain was susceptible to the positive control amoxicillin with MIC (MBC) values of 0.032 (0.063) µg/mL.

Table 2

Test material	Slope ± SE	Urease IC50, mg/mL (95% CL)
mEtOAc Fr.	0.81 ± 0.056	0.34 (0.30 – 0.39)
fEtOAc Fr.	1.25 ± 0.118	0.35 (0.31 – 0.40)
mWater Fr.	1.56 ± 0.269	1.26 (1.02 – 1.55)
fWater Fr.	0.47 ± 0.077	1.40 (1.12 – 1.74)
PS Fr.	1.59 ± 0.265	29.67 (26.12 – 33.70)
mHexane Fr.	2.13 ± 0.173	30.26 (28.53 – 32.10)
fHexane Fr.		ND
Thiourea	1.65 ± 0.215	0.055 (0.049 – 0.062)

Based on urease IC₅₀ data presented in Table 2, mEtOAc Fr. and fEtOAc Fr. displayed strong urease inhibitory activity with IC₅₀ values of 0.34 and 0.35 mg/mL, respectively, with a non-significant difference (p > 0.05). This was followed by the inhibitory activity of mWater Fr. and fWater Fr. (IC₅₀ values of 1.26 and 1.40 mg/mL, respectively). Besides, both mEtOAc Fr. and fEtOAc Fr. caused a steep dose-response curve of the percentage of urease inhibitory activity and produced a complete inhibition against the urease at 2.5 mg/mL, whereas mWater Fr. and fWater Fr. showed a complete inhibition against the urease at 3 and >5 mg/mL, respectively (Figure 3). Moreover, PS Fr., mHexane Fr. and fHexane Fr. gave very weak or no inhibitory activity towards the enzyme. All the fractions exhibited lower urease inhibitory activity than the positive control thiourea (IC₅₀, 0.055 mg/mL) (Table 2).

Figure 3 Table 3

Test material	Slope ± SE	DPPH IC50, mg/mL (95% CL)
fEtOAc Fr.	2.322 ± 0.339	11.83 (10.48 – 13.36)
mEtOAc Fr.	2.972 ± 0.421	14.75 (13.52 – 16.09)
PS Fr.	3.217 ± 0.256	26.04 (24.77 – 27.38)
mWater Fr.	3.03 ± 0.365	28.66 (26.6 – 30.87)
fWater Fr.	1.879 ± 0.211	34.51 (31.90 – 37.34)
mHexane Fr.		ND
fHexane Fr.		ND
Acid ascorbic	2.712 ± 0.567	0.057 (0.048 – 0.065)

Based on DPPH IC₅₀ values presented in Table 3, fEtOAc Fr. displayed the greatest antioxidant activity in the DPPH assay (IC₅₀ of 11.83 mg/mL), followed by mEtOAc Fr. (IC₅₀ of 14.75 mg/mL), with a significant difference (p < 0.01). Moreover, PS Fr., mWater Fr. and fWater Fr. showed weak or very weak antioxidant activity (IC₅₀, 28.66 – 34.51 mg/mL). In addition, fEtOAc Fr. caused a steep dose-response curve of percentage of DPPH radical scavenging activity and complete inhibition at 40 mg/mL (Figure 4). Fractions mHexane Fr. and fHexane Fr. had no radical scavenging activity. Overall, all of these fractions showed significantly weaker DPPH radical scavenging activity than the positive control acid ascorbic (IC₅₀ of 0.057 mg/mL) (Table 3).

Figure 4

Oxidative stress and chronic inflammation have been known to play critical roles in the pathogenesis of gastritis and gastric ulcers caused by various stimuli, including H. pylori23. Various physiological effects of H. erinaceus (lion's mane mushroom) have been presented, including anti-aging, anti-cancer, anti-gastritis, and anti-metabolic disease properties1, 6, 7, 8, 24. The mushroom's bioactive components, such as erinacines and hericenones, were extracted or concentrated as nutraceuticals because they have been revealed to act as the active principles for nerve growth factor synthesis and in neuroprotective function25, 26, 27. H. erinaceus is quite rare in the wild. However, by artificial cultivation techniques, its fruiting body and mycelium are nowadays being produced as raw materials for culinary and medicinal use. H. erinaceus has become attractive as a disease-preventing functional food and as a source of medicines. H. erinaceus aqueous and 50% EtOH extracts were demonstrated to possess immune-stimulatory activity to protect infected mice against Salmonella Typhimurium12. Methanolic extract from a pure culture of H. erinaceus mycelium was reported to produce weak inhibitory activity against Bacillus cereus, B. subtilis, Enterococcus faecalis, Salmonella sp., Shigella sp. and Plesiomonas shigelloides11. However, EtOH extract from fruiting body of H. erinaceus has been shown to exhibit similar growth inhibitory effects on several strains of H. pylori9, 10, 13. Petroleum ether, chloroform, and EtOAc fractions from the fruiting body extract were reported to exhibit a stronger growth inhibitory activity than the crude extract against H. pylori9, 13. In our present study, mEtOAc Fr. and fEtOAc Fr. from mycelium and culture filtrate of H. erinaceus displayed stronger anti-H. pylori activity than the polysaccharide, hexane and water fractions.

Findings on the mechanism of H. erinaceus action against H. pylori have indicated that the mushroom extracts helped prevent oxidative stress in human gastric mucosa epithelium cell18 and inhibit the adhesion ability of H. pylori to the host cell, thereby contributing to reduction of the bacterial infection in the stomach of test mice10. The urease-producing ability of H. pylori has been known to play a crucial role in infection and survival of the pathogen in the stomach. Therefore, inhibition of the urease activity has also been considered as an alternative strategy for the treatment of the H. pylori infection. Hot water extracts, ether and EtOAc fractions of some mushrooms, such as Ganoderma lucidum, Coriolus versicolor, Agaricus bisporus and Gyrophora esculenta, were reported to possess growth inhibitory activity against H. pylori, but these extracts and fractions showed no inhibitory effect on H. pylori urease activity28. Several studies have reported on the inhibitory effect of plant preparations and phytochemicals on H. pylori urease19, 22, 29. However, no information was reported on the inhibitory activity of H. erinaceus preparations or its constituents against urease activity of H. pylori. In our present study, the EtOAc fractions from both mycelium and culture filtrate of H. erinaceus exhibited growth inhibitory activity against H. pylori. They had a stronger inhibitory urease than the water fractions, while the polysaccharide and hexane fractions showed no effect.

MeOH extracts from fresh fruiting body and mycelium of H. erinaceus were found to have antioxidant activity in DPPH free radical scavenging, and the activity was not due to phenolic compounds in H. erinaceus extracts11. It was reported that polysaccharides purified from liquid culture of H. erinaceus mycelium enhanced the growth of rat adrenal nerve cells and improved the extension of neurites of PC12 cells30. The polysaccharide fraction from H. erinaceus mycelium was found to possess anti-ulcer and anti-gastritis activities31, 32. Moreover, the antioxidant capacity of the polysaccharide fraction from H. erinaceus mycelium was higher than that of hot water extract from H. erinaceus fruiting body18. In our present study, the polysaccharide fraction from the culture filtrate of H. erinaceus showed a lower antioxidant effect than the EtOAc fractions from both the mycelium and culture filtrate. These results indicate that the EtOAC fractions from the mycelium and culture filtrate of H. erinaceus could exert growth-inhibiting and urease inhibitory effects on H. pylori to enhance antioxidant defense and protect the human stomach from H. pylori infection. More research is needed to prove the safety of the H. erinaceus mycelium and culture filtrate fractions and their in vivo efficacies in the treatment of H. pylori infection.

The present study revealed that the EtOAC fractions derived from the mycelium and culture filtrate of H. erinaceus exhibited pronounced antioxidant and inhibitory effects against H. pylori. The results suggest that the in vitro culture of mycelium and culture filtrate of H. erinaceus could be further studied to develop potent antibacterial products for the treatment of H. pylori infection.

ATCC: American Type Culture Collection

CFU: Colony forming units

MIC: Minimal inhibitory concentration

MBC: Minimal bactericidal concentration

mHexane Fr.: Hexane fraction derived from mycelium

mEtOAc Fr.: Ethyl acetate fraction derived from mycelium

mWater Fr.: Water fraction derived from mycelium

NBS: newborn bovine serum

PS Fr.: Polysachaccride fraction derived from culture filtrate

fHexane Fr.: Hexane fraction derived from culture filtrate

fEtOAc Fr.: Ethyl acetate fraction derived from culture filtrate

fEtOAc Fr.: Water fraction derived from culture filtrate

All authors gratefully acknowledge the financial support from Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 106-YS.06-2015.17.

LTM Ngan, TT Hieu and PT Ho conceived and designed the experiments. LTM Ngan, TT Hieu, NT Vi, DTM Tham and LTT Loan performed the experiments. LTM Ngan, TT Hieu and NT Vi analyzed and interpreted the data. LTM Ngan and TT Hieu participated in drafting and writing the article. All authors read and approved the manuscript.

Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 106-YS.06-2015.17.

Data and materials used and/or analysed during the current study are available from the corresponding author on reasonable request.

Not applicable.

Not applicable.

The authors declare that they have no competing interests.

Hetland G, Tangen JM, Mahmood F, Mirlashari MR, Nissen-Meyer LSH, Nentwich I, Therkelsen SP, Tjønnfjord GE, Johnson E. Antitumor, anti-inflammatory and antiallergic effects of Agaricus blazei mushroom extract and the related medicinal Basidiomycetes mushrooms, Hericium erinaceus and Grifola frondosa: A review of preclinical and clinical studies. Nutrients. 2020;12(5):1339 https://doi.org/10.3390/nu12051339 32397163 Lee EW, Shizuki K, Hosokawa S, Suzuki M, Suganuma H, Inakuma T, Li J, Ohnishi-Kameyama M, Nagata T, Furukawa S, Kawagish H. Two novel diterpenoids, erinacines H and I from the mycelia of Hericium erinaceum. Biosci Biotechnol Biochem. 2000;64(11):2402-2405 https://doi.org/10.1271/bbb.64.2402 11193408 Kenmoku H, Shimai T, Toyomasu T, Kato N, Sassa T. Erinacine Q, a new erinacine from Hericium erinaceum, and its biosynthetic route to erinacine C in the basidiomycete. Biosci Biotechnol Biochem. 2002;66(3):571-575 https://doi.org/10.1271/bbb.66.571 12005051 Ashour A, Amen Y, Allam AE, Kudo T, Nagata M, Ohnuki K, Shimizu K. New isoindolinones from the fruiting bodies of the fungus Hericium erinaceus. Phytochem Lett. 2019;32:10-14 https://doi.org/10.1016/j.phytol.2019.04.017 Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008;31(9):1727-1732 https://doi.org/10.1248/bpb.31.1727 18758067 Kim SP, Kang MY, Kim JH, Nam SH, Friedman M. Composition and mechanism of antitumor effects of Hericium erinaceus mushroom extracts in tumor-bearing mice. J Agric Food Chem. 2011;59(18):9861-9869 https://doi.org/10.1021/jf201944n 21846141 Diling C, Xin Y, Chaoqun Z, Jian Y, Xiaocui T, Jun C, Ou S, Yizhen X. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota. Oncotarget. 2017;8(49):85838-85857 https://doi.org/10.18632/oncotarget.20689 29156761 Xu H, Wu PR, Shen ZY, Chen XD. Chemical analysis of Hericium erinaceum polysaccharides and effect of the polysaccharides on derma antioxidant enzymes, MMP-1 and TIMP-1 activities. Int J Biol Macromol. 2010;47(1):33-36 https://doi.org/10.1016/j.ijbiomac.2010.03.024 20380848 Liu JH, Li L, Shang XD, Zhang JL, Tan Q. Anti-Helicobacter pylori activity of bioactive components isolated from Hericium erinaceus. J Ethnopharmacol. 2016;183:54-58 https://doi.org/10.1016/j.jep.2015.09.004 26364939 Wang G, Zhang X, Maier SE, Zhang L, Maier RJ. In vitro and in vivo inhibition of Helicobacter pylori by ethanolic extracts of lion's mane medicinal mushroom, Hericium erinaceus (Agaricomycetes). Int J Med Mushrooms. 2019;21(1):1-11 https://doi.org/10.1615/IntJMedMushrooms.2018029487 30806251 Wong KH, Sabaratnam V, Abdullah N, Kuppusamy UR, Naidu M. Effects of cultivation techniques and processing on antimicrobial and antioxidant activities of Hericium erinaceus (Bull.: Fr.) Pers. extracts. Food Technol Biotechnol. 2009;47(1):47-55 https://www.ftb.com.hr/images/pdfarticles/2009/January-March/47-47.pdf Kim SP, Moon E, Nam SH, Friedman M. Hericium erinaceus mushroom extracts protect infected mice against Salmonella Typhimurium-Induced liver damage and mortality by stimulation of innate immune cells. J Agric Food Chem. 2012;60(22):5590-5596 https://doi.org/10.1021/jf300897w 22624604 Shang X, Tan Q, Liu R, Yu K, Li P, Zhao GP. In vitro anti-Helicobacter pylori effects of medicinal mushroom extracts, with special emphasis on the Lion's Mane mushroom, Hericium erinaceus (higher Basidiomycetes). Int J Med Mushrooms. 2013;15(2):163-174 https://doi.org/10.1615/IntJMedMushr.v15.i2.50 23557368 Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119(9):2475-2487 https://doi.org/10.1172/JCI38605 19729845 Negrei C, Boda D. The Mechanisms of action and resistance to fluoroquinolone in Helicobacter pylori Infection. In: Roesler. Trends in Helicobacter pylori Infection BM editor. IntechOpen 2014;349 https://doi.org/10.5772/57081 Lee JS, Hong EK. Hericium erinaceus enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells. Cancer Lett. 2010;297(2):144-154 https://doi.org/10.1016/j.canlet.2010.05.006 20554107 Kuo HC, Lu CC, Shen CH, Tung SY, Hsieh MC, Lee KC, Lee LY, Chen CC, Teng CC, Huang WS, Chen TC. Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. J Transl Med. 2016;14:78 https://doi.org/10.1186/s12967-016-0831-y 26988860 Wang M, Kanako N, Zhang Y, Xiao X, Gao Q, Tetsuya K. A unique polysaccharide purified from Hericium erinaceus mycelium prevents oxidative stress induced by H2O2 in human gastric mucosa epithelium cell. PLoS ONE. 2017;12(7): e0181546 https://doi.org/10.1371/journal.pone.0181546 28742114 Ngan LTM, Moon JK, Shibamoto T, Ahn YJ. Growth-inhibiting, bactericidal, and urease inhibitory effects of Paeonia lactiflora root constituents and related compounds on antibiotic-susceptible and -resistant strains of Helicobacter pylori. J Agric Food Chem. 2012;60(36):9062-9073 https://doi.org/10.1021/jf3035034 22891951 Ngan L. T. M. Antibacterial activity of ethanolic extracts of some Vietnamese medicinal plants against Helicobacter pylori. AIP Conference Proceedings. 2017; 1878(1):020030 https://doi.org/10.1063/1.5000198 Icatlo FC, Jr Kuroki M, Kobayashi C, Yokoyama H, Ikemori Y, Hashi T, Kodama Y. Affinity purification of Helicobacter pylori urease. Relevance to gastric mucin adherence by urease protein. J Biol Chem. 1998;273(29):18130-18138 https://doi.org/10.1074/jbc.273.29.18130 9660771 Tran TH, Truong THH, Nguyen TTL, Nguyen VMH, Nguyen TMN, Luong TMN. Growth-inhibiting, bactericidal, antibiofilm, and urease inhibitory activities of Hibiscus rosa sinensis L. flower constituents toward antibiotic sensitive- and resistant-strains of Helicobacter pylori. ACS Omega. 2020;5(32):20080-20089 https://doi.org/10.1021/acsomega.0c01640 32832762 Al-Sayed E, El-Naga RN. Protective role of ellagitannins from Eucalyptus citriodora against ethanol-induced gastric ulcer in rats: Impact on oxidative stress, inflammation and calcitonin-gene related peptide. Phytomed Int J Phytother Phytopharmacol. 2015;22(1):5-15 https://doi.org/10.1016/j.phymed.2014.10.002 25836864 Wang M, Gao Y, Xu D, Konishi T, Gao Q. Hericium erinaceus (Yamabushitake): a unique resource for developing functional foods and medicines. Food Funct. 2014;5(12):3055-3064 https://doi.org/10.1039/C4FO00511B 25317734 Kim KH, Noh HJ, Choi SU, Lee KR. Isohericenone, a new cytotoxic isoindolinone alkaloid from Hericium erinaceum. J Antibiot. 2012;65(11):575-577 https://doi.org/10.1038/ja.2012.65 22828965 Zhang CC, Yin X, Cao CY, Wei J, Zhang Q, Gao JM. Chemical constituents from Hericium erinaceus and their ability to stimulate NGF-mediated neurite outgrowth on PC12 cells. Bioorg Med Chem Let. 2015;25(22):5078-5082 https://doi.org/10.1016/j.bmcl.2015.10.016 26481911 Trovato A, Siracusa R, Di Paola R, Scuto M, Ontario ML, Bua O, Di Mauro P, Toscano MA, Petralia CC, Maiolino L, Serra A. Redox modulation of cellular stress response and lipoxin A4 expression by Hericium erinaceus in rat brain: relevance to Alzheimer's disease pathogenesis. Immun Ageing. 2016;13:23 https://doi.org/10.1186/s12979-016-0078-8. 27398086 Kim DH, Bae EA, Jang IS, Han MJ. Anti-Helicobacter pylori activity of mushrooms. Arch Pharm Res. 1996;19:447-449 https://doi.org/10.1007/BF02986009 Lee HK, Song HE, Lee HB, Kim CS, Koketsu M, Ngan LTM, Ahn YJ. Growth inhibitory, bactericidal, and morphostructural effects of dehydrocostus lactone from Magnolia sieboldii leaves on antibiotic-susceptible and-resistant strains of Helicobacter pylori. PLoS One. 2014;9(4):e95530 https://doi.org/10.1371/journal.pone.0095530 24747984 Park YS, Lee HS, Won MH, Lee JH, Lee SY, Lee HY. Effect of an exo-polysaccharide from the culture broth of Hericium erinaceus on enhancement of growth and differentiation of rat adrenal nerve cells. Cytotechnology. 2002;39(3):155-162 https://doi.org/10.1023/A:1023963509393 19003308 Wang M, Yang G, Xu D, Gao Q. A polysaccharide from cultured mycelium of Hericium erinaceus and its anti-chronic atrophic gastritis activity. Int J Biol Macromol. 2015;81:656-661 https://doi.org/10.1016/j.ijbiomac.2015.08.043 26314904 Wang M, Konishi T, Gao Y, Xu D, Gao Q. Anti-gastric ulcer activity of polysaccharide fraction isolated from mycelium culture of lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes). Int J Med Mushrooms. 2015;17(11):1055-1060 https://doi.org/10.1615/IntJMedMushrooms.v17.i11.50 26853960